These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 25591547)
61. A trade agreement's impact on access to generic drugs. Shaffer ER; Brenner JE Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626 [TBL] [Abstract][Full Text] [Related]
62. Impact of parallel trade on pharmaceutical firm's profits: rise or fall? Guo S; Hu B; Zhong H Eur J Health Econ; 2013 Apr; 14(2):345-55. PubMed ID: 22286662 [TBL] [Abstract][Full Text] [Related]
63. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Danzon PM; Ketcham JD Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334 [TBL] [Abstract][Full Text] [Related]
64. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity. Berger JM Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292 [No Abstract] [Full Text] [Related]
65. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement. Gaspar Ernesto LM; Dias Loureiro RM PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862 [TBL] [Abstract][Full Text] [Related]
66. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary). Cross G Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444 [TBL] [Abstract][Full Text] [Related]
67. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. Inotai A; Kaló Z Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392 [No Abstract] [Full Text] [Related]
68. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings. Kanavos P Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392 [TBL] [Abstract][Full Text] [Related]
69. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
70. [Generic drugs in the medical-economic context of drug prescriptions]. Bouvenot G; Villani P; Bouvenot J Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093 [TBL] [Abstract][Full Text] [Related]
71. Endogenous versus exogenous generic reference pricing for pharmaceuticals. Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248 [TBL] [Abstract][Full Text] [Related]
72. How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Vogler S; Fischer S Health Policy; 2020 Dec; 124(12):1287-1296. PubMed ID: 33032846 [TBL] [Abstract][Full Text] [Related]
73. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan]. Pflieger M; Bertram D Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054 [TBL] [Abstract][Full Text] [Related]
74. The UK pharmaceutical market. An overview. Towse A Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432 [TBL] [Abstract][Full Text] [Related]
75. Price comparison of high-cost originator medicines in European countries. Vogler S; Zimmermann N; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050 [TBL] [Abstract][Full Text] [Related]
76. Drug shortages in European countries: a trade-off between market attractiveness and cost containment? Pauwels K; Huys I; Casteels M; Simoens S BMC Health Serv Res; 2014 Sep; 14():438. PubMed ID: 25257912 [TBL] [Abstract][Full Text] [Related]
77. Reference pricing of pharmaceuticals. Brekke KR; Königbauer I; Straume OR J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769 [TBL] [Abstract][Full Text] [Related]
78. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products]. Lehmann B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107 [TBL] [Abstract][Full Text] [Related]
79. Drug shortages. Part 2: Trends, causes and solutions. Aronson JK; Heneghan C; Ferner RE Br J Clin Pharmacol; 2023 Oct; 89(10):2957-2963. PubMed ID: 37455465 [TBL] [Abstract][Full Text] [Related]
80. Differential pricing of new pharmaceuticals in lower income European countries. Kaló Z; Annemans L; Garrison LP Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]